Skip to main content

Day: February 23, 2022

UPDATE — Logansport Financial Corp. Announces First Quarter Dividend

LOGANSPORT, Ind., Feb. 23, 2022 (GLOBE NEWSWIRE) — Logansport Financial Corp. (OTCBB – Symbol “LOGN”), an Indiana corporation which is the holding company for Logansport Savings Bank, a State Commercial bank located in Logansport, Indiana, announces that Logansport Financial Corp. has declared a quarterly cash dividend of $.40 on each share of its common stock for the first quarter of 2022. The dividend is payable on April 22, 2022 to the holders of record on March 22, 2022. Contact: Kristie Richey Chief Financial Officer Phone 574-722-3855 Fax 574-722-3857

Continue reading

Amdocs Unveils Revolutionary, Flexible Monetization Offering Designed to Match End Users’ Unique Needs in the 5G Era

Amdocs Freestyle Billing enables operators to support end users’ preferred payment and business model per experience; introduces intelligent billing and monetization options, partner ecosystem management and improves real-time billing visibility JERSEY CITY, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) — Amdocs (NASDAQ: DOX), a leading provider of software and services to communications and media companies, today introduced Amdocs Freestyle Billing solution to enable service providers to evolve their billing with a next-generation, flexible, customizable offering, future-proofed for the endless possibilities of 5G experiences as well as new services, physical and virtual goods. Several tier-1 North American service providers have already integrated this solution, improving existing customer experiences and preparing their business for...

Continue reading

Property Insurance Shopping Drops into Negative Figures for First Time in 18 Months

Property and auto insurance shopping slows at end of 2021 CHICAGO, Feb. 23, 2022 (GLOBE NEWSWIRE) — Despite optimism at the outset of the quarter, property and auto insurance shopping trended below 2020 levels at the end of 2021. TransUnion’s (NYSE: TRU) latest Personal Lines Insurance Shopping Report found auto insurance shopping was down an average of 12.5%, while property insurance shopping dropped an average of 3.4%, compared to the same time period in 2020. Record-breaking prices for both new and used vehicles deterred many consumers from auto shopping, and in turn, reduced insurance shopping by as much as 16.4%, compared to Q4 2020. However, insurance premiums have continued to rise in response to rising severity trends, which is prompting more consumers to switch carriers, according to a recent report by J.D. Power. While...

Continue reading

Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular Panel at the Cowen 42nd Annual Health Care Conference. The panel will be held on Monday, March 7, 2022 at 9:10 a.m. Eastern Time. A live webcast will be available on the Investor Relations section of the Company’s website at www.entradatx.com, or by clicking here. A replay will be available on the Entrada website for 90 days following the event. About Entrada Therapeutics Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by...

Continue reading

Jounce Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Wednesday, March 2, 2022

CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update before market open on Wednesday, March 2, 2022. Jounce Therapeutics’ management team will host a live conference call and webcast at 8:00 a.m. ET. Conference Call and Webcast To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 8998936. The live webcast can be accessed under “Events & Presentations” in the Investors and Media section of the company’s website at www.jouncetx.com. The webcast will...

Continue reading

Rhythm Pharmaceuticals Announces Promotions within its Executive Leadership Team

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced the promotions of Joe Shulman to Chief Technical Officer, Patrick Kleyn, Ph.D., to Senior Vice President and Head of Translational Research and Development, and Elisabeth Crönert-Bendell, M.D., to Senior Vice President and Head of Strategy. “We are pleased to announce the promotions of three exceptionally talented and influential leaders on Rhythm’s executive leadership team,” said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm. “Joe, Patrick and Elisabeth continue to play vital roles in our efforts to build a global organization, deliver IMCIVREE® (setmelanotide) to...

Continue reading

South Star Battery Metals Announces Approval of All Final Exploration Reports of Santa Cruz Mine by Brazilian Mining Authority and Launch of Product Information Bulletins for Phase 1 Operations

Figure 1 Santa Cruz Phase 1 Product Information Bulletins.VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) — South Star Battery Metals Corp. (“South Star” or the “Company”) (TSXV: STS) (OTCQB: STSBF), is pleased to announce that it has received approval from the Brazilian Mining Authority (“ANM”) on February 22th, 2022 of the final exploration reports for the remaining 6 of the 13 claims of the Santa Cruz Graphite Mine in Brazil. In addition, the Company has launched Product Information Bulletins (“PIBs”) for a range of concentrate products for Phase 1 operations. The approval of the Final Exploration Reports for all 13 claims totaling approximately 13,000 hectares is presented in Table 1. The other 7 claims had the final exploration reports previously approved on February 8th, 2022 (See February 9th, 2022 Press Release).Claim...

Continue reading

aTyr Pharma to Participate in Panel at National Institutes of Health Rare Disease Day®

Panel to take place on Monday, February 28, 2022, at 2:55pm EST / 11:55am PST SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a panel as part of the National Institutes of Health (NIH) Rare Disease Day® virtual conference on Monday, February 28, 2022, at 2:55pm EST / 11:55am PST. The panel, “Successful Clinical Trial Enrollment with True Advocacy Collaboration During Challenging Times,” will discuss strategies for clinical trial recruitment successes, including lessons learned from aTyr’s experience conducting a Phase 1b/2a study of efzofitimod (ATYR1923) in patients...

Continue reading

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Collaboration to identify patient-selection biomarkers for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment CAMBRIDGE, Mass. and PARIS, Feb. 23, 2022 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify biomarkers of response to refine patient selection to guide and accelerate the clinical development of Cyclerion’s investigational therapeutics for neurological and neuropsychiatric diseases associated with cognitive impairment. Ariana Pharma’s proprietary KEM® (Knowledge Extraction and Management) eXplainable Artificial Intelligence (xAI) technology aims at significantly increasing success rates and accelerating...

Continue reading

ibex Celebrates 5-Year Anniversary of ibex Cares with More Than $250,000 in Donations Earmarked for Local Charities in 2022

Philanthropic program gives back to local communities worldwideibex Celebrates 5-Year Anniversary of ibex Cares ibex Celebrates 5-Year Anniversary of ibex Cares.WASHINGTON, Feb. 23, 2022 (GLOBE NEWSWIRE) — ibex (NASDAQ: IBEX), a leading global provider of business process outsourcing (BPO) and customer engagement technology solutions, is celebrating the 5-year anniversary of ibex Cares, the company’s global philanthropic program that supports local communities where the company operates. This year, the program will be responsible for giving more than $250,000 in donations to local charities and causes. ibex is committed to meaningfully investing in its employees and the communities where they live and work. Employees themselves choose the local charities they want to support and strive to make a difference in the lives of the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.